35,000 stock options granted to Skye Bioscience (SKYE) director

Rhea-AI Filing Summary

Skye Bioscience director Grayson Paul A. received a grant of stock options on February 6, 2026. The award covers 35,000 stock options to buy Skye Bioscience common stock at an exercise price of $0.82 per share, held as a direct ownership position.

According to the footnote, the option vests in equal monthly installments over a one-year period beginning January 19, 2026. After this transaction, the director beneficially holds 35,000 derivative securities related to Skye Bioscience common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grayson Paul A.

(Last) (First) (Middle)

C/O SKYE BIOSCIENCE, INC.

11250 EL CAMINO REAL, SUITE 100

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.82	02/06/2026		A		35,000		(1)	02/06/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026.

Remarks:

	/s/ Kaitlyn Arsenault, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Skye Bioscience (SKYE) report for Grayson Paul A.?

Skye Bioscience reported a stock option grant to director Grayson Paul A. He received 35,000 stock options on February 6, 2026, giving him the right to buy Skye Bioscience common shares at a fixed exercise price of $0.82 per share.

How many Skye Bioscience (SKYE) stock options were granted and at what price?

The grant covers 35,000 stock options with an exercise price of $0.82 per share. These options allow the director to purchase Skye Bioscience common stock at that price, regardless of future market price, once the options are vested.

When do the new Skye Bioscience (SKYE) stock options start and finish vesting?

The options begin vesting on January 19, 2026. They vest in equal monthly installments over a one-year period starting on that date, so the award gradually becomes exercisable each month until fully vested after twelve months.

What is the total number of derivative securities Grayson Paul A. holds in Skye Bioscience (SKYE)?

After this grant, the director beneficially owns 35,000 derivative securities. These represent the stock options reported in the filing, all held as a direct position related to Skye Bioscience common stock, with no additional derivative holdings disclosed.

Is the Skye Bioscience (SKYE) insider transaction a purchase or a grant of options?

The transaction is a grant of stock options reported with transaction code “A,” indicating an award. It does not reflect an open-market stock purchase or sale, but rather the issuance of options as part of the director’s compensation.